Holen Sie sich die Stockscreener-App
21.98
3.97%
0.84
Handel nachbörslich:
21.98
Castle Biosciences Inc Aktie (CSTL) Neueste Nachrichten
Castle Biosciences, Inc. (NASDAQ:CSTL) Stake Raised by Geode Capital Management LLC - Defense World
When Should You Buy Castle Biosciences, Inc. (NASDAQ:CSTL)? - simplywall.st
Castle Biosciences: Steady Revenue Stream, But Medicare Reimbursement Loss A Concern - Seeking Alpha
Castle Biosciences to Release First Quarter 2025 Financial Resul - GuruFocus
Castle Biosciences to Release First Quarter 2025 Financial Results and Host Conference Call on Monday, May 5, 2025 - GlobeNewswire
Castle Biosciences Sets Q1 Earnings Date: Key Financial Updates Coming May 5 - Stock Titan
Castle Biosciences, Inc. (NASDAQ:CSTL) Shares Acquired by Franklin Resources Inc. - Defense World
28,903 Shares in Castle Biosciences, Inc. (NASDAQ:CSTL) Acquired by Arrowstreet Capital Limited Partnership - Defense World
Vanguard Group Inc. Has $48.84 Million Stake in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Corebridge Financial Inc. Has $343,000 Stock Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences CEO Derek Maetzold sells $113,931 in stock By Investing.com - Investing.com Canada
KLP Kapitalforvaltning AS Buys New Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences CEO Derek Maetzold sells $113,931 in stock - Investing.com
SEC Form DEF 14A filed by Castle Biosciences Inc. - Quantisnow
American Century Companies Inc. Has $1.84 Million Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences backs esophageal cancer awareness By Investing.com - Investing.com South Africa
Castle Biosciences backs esophageal cancer awareness - Investing.com
Castle Biosciences Strengthens Commitment to Esophageal Cancer Awareness Through Collaborative Partnerships - GlobeNewswire
Game-Changing Esophageal Cancer Detection: Castle Bio Partners With Top Medical Networks - Stock Titan
Sei Investments Co. Boosts Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences Honored with a Top Workplaces USA Award for Fourth Consecutive Year - GlobeNewswire
Castle Biosciences Ranks #30 Among Best U.S. Workplaces: 85% Employee Engagement Score - Stock Titan
Castle Biosciences, Inc. (NASDAQ:CSTL) Given Average Recommendation of “Buy” by Brokerages - Defense World
Publication of Data from Prospective, Multicenter Study Demonstrates Positive Survival Outcomes in Patients with Low-Risk Melanoma Who Avoided Sentinel Lymph Node Biopsy with Information from Castle Biosciences' DecisionDx®-Melanoma Test - The Manila Times
Publication of Data from Prospective, Multicenter Study - GlobeNewswire
Publication of Data from Prospective, Multicenter Study Demonstrates Positive Survival Outcomes in Patients with Low-Risk Melanoma Who Avoided Sentinel Lymph Node Biopsy with Information from Castle Biosciences’ DecisionDx®-Melanoma Test - Yahoo Finance
Are Castle Biosciences, Inc.'s (NASDAQ:CSTL) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market? - Yahoo Finance
Teacher Retirement System of Texas Makes New $253,000 Investment in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences to Present New Data at EADO Supporting the Clinical Value of the DecisionDx®-Melanoma Test in Guiding Risk-Aligned Management of Patients with Melanoma - The Manila Times
Castle Biosciences to Present New Data at EADO Supporting - GlobeNewswire
Breakthrough Melanoma Test Data Reveals Critical Survival Predictions for High-Risk Patients - Stock Titan
Castle Biosciences CEO Derek Maetzold sells $114,573 in stock - Investing.com Australia
Castle Biosciences CEO Derek Maetzold sells $114,573 in stock By Investing.com - Investing.com India
Castle Biosciences' DecisionDx®-SCC Data Earns Top Five Abstract at NCCN 2025, Shows Significantly Enhanced Risk Stratification Beyond Current Staging Within NCCN Risk Groups - The Manila Times
Castle Biosciences' DecisionDx®-SCC Data Earns Top Five - GlobeNewswire
Breakthrough Study: Top-Ranked Cancer Test Doubles Accuracy in Predicting Metastatic Risk - Stock Titan
Castle Biosciences, Inc. (NASDAQ:CSTL) Position Trimmed by Charles Schwab Investment Management Inc. - Defense World
Castle Biosciences, Inc. (NASDAQ:CSTL) Shares Acquired by Bank of New York Mellon Corp - Defense World
Bank of New York Mellon Corp Has $2.25 Million Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - The AM Reporter
CSTL Gears Up to Report Q4 Earnings: Here's What You Should Know - MSN
Beyond the Lab: Artificial Intelligence - Drug Target Review
US Bancorp DE Sells 3,413 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Assetmark Inc. Has $118,000 Stock Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences, Inc. (NASDAQ:CSTL) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Castle Biosciences CEO Derek Maetzold sells $585,673 in stock - Investing.com India
Castle Biosciences CEO Derek Maetzold sells $585,673 in stock By Investing.com - Investing.com UK
New Data to be Presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting Further Strengthens Evidence Supporting the Clinical Value of Castle Biosciences' Dermatology Portfolio - Business Wire
Castle Biosciences Inc to Host Earnings Call - ACCESS Newswire
Solid Earnings Reflect Castle Biosciences' (NASDAQ:CSTL) Strength As A Business - Yahoo Finance
Castle Biosciences, Inc. (NASDAQ:CSTL) Shares Sold by Rhumbline Advisers - Defense World
What is Leerink Partnrs’ Forecast for CSTL Q1 Earnings? - Armenian Reporter
Castle Biosciences, Inc. (NASDAQ:CSTL) Stock Position Boosted by Truist Financial Corp - Defense World
6.96%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):